To assess the efficacy of intravitreal anti—vascular endothelial growth factor (VEGF) treatment of vascularized pigment epithelial detachment (PED) due to age-related macular degeneration (AMD).
Methods
A total of 26 patients with vascularized PED secondary to AMD were retrospectively analyzed and treated with anti-VEGF intravitreal injections according to a PRN regimen after 3 initial injections. Best-corrected visual acuity (BCVA), optical coherence tomography, and fluorescein angiography were performed at baseline and quarterly.
Results
Mean follow-up ranged from 9 to 26 months (mean 13.5). There was a deterioration in mean BCVA from 0.46 at baseline to 0.79 logMAR at 12 months (p<0.001). The mean PED greatest linear diameter (GLD) increased from 4499 at baseline to 5206 μm at 1-year follow-up (p<0.001). The mean PED maximum height decreased from 669 μm at baseline to 305 μm at 1-year follow-up (p = 0.001). The mean central retinal thickness (CRT) was unchanged (from 277 to 209 μm at 1 year follow-up) (p = 0.099). No effect was seen on the change of VA according to groups of baseline predictors as defined by the medial value: baseline VA, PED height, and CRT (p>0.10). There was a borderline trend (p = 0.064) that GLD affected response to treatment. The mean number of injections was 5.5 (3 to 9). Seven out of 26 (27%) patients developed a retinal pigment epithelium (RPE) tear.
Conclusions
Intravitreal anti-VEGF therapy, with a PRN regimen, did not prevent visual acuity loss or RPE tear.
PolinerLSOlkRJBurgessDGordonMENatural history of retinal pigment epithelial detachments in age-related macular degeneration.Ophthalmology. 198693543–51.
2.
PauleikhoffDLöffertDSpitalGPigment epithelial detachment in the elderly.Clinical differentiation, natural course and pathogenetic implications.Graefes Arch Clin Exp Ophthalmol. 2002240533–8.
3.
CasswellAGKohenDBirdACRetinal pigment epithelial detachments in the elderly: classification and outcome.Br J Ophthalmol. 198569397–403.
4.
Da PozzoSParodiMBRavalicoGA pilot study of ICG-guided laser photocoagulation for occult choroidal neovascularization presenting as a focal spot in age-related macular degeneration.Int Ophthalmol. 200124187–94.
5.
SlakterJSYannuzziLASorensonJAGuyerDRHoACOrlockDAA pilot study of indocyanine green videoangiography-guided laser photocoagulation of occult choroidal neovascularization in age-related macular degeneration.Arch Ophthalmol. 1994112465–72.
6.
KoenigFSoubraneGCoscasG[Retinal pigment epithelial tears after photocoagulation in age-related macular degeneration.]J Fr Ophtalmol. 198912775–80.
7.
The Moorfields Macular Study Group.Treatment of senile disciform macular degeneration: a single-blind randomised trial by argon laser photocoagulation.Br J Ophthalmol. 198266745–53.
8.
Axer-SiegelREhrlichRRosenblattIPhotodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.Arch Ophthalmol. 2004122453–9.
9.
GotoSGomiFUenoCNishidaKReduced-fluence photodynamic therapy for subfoveal serous pigment epithelial detachment with choroidal vascular hyperpermeability.Am J Ophthalmol. 2012154865–71.
10.
JonasJBStruevenVKamppeterBAHarderBSpandauUHSchlichtenbredeFVisual acuity change after intravitreal triamcinolone in various types of exudative age-related macular degeneration.J Ocul Pharmacol Ther. 200622370–6.
11.
BashshurZFHaddadZASchakalARJaafarRFSaadANoureddinBNIntravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study.Am J Ophthalmol. 200914859–65.
12.
LalwaniGARosenfeldPJFungAEA variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.Am J Ophthalmol. 200914843–58.
13.
BashshurZFSchakalAREl-MollayessGMArafatSJaafarDSaltiHIRanibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration.Retina. 201131636–44.
14.
SchaalKBEnglerCSchüttFScheuerleADithmarS[Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD.]Ophthalmologe. 2008105538–43.
15.
RosenfeldPJBrownDMHeierJSMARINA Study Group.Ranibizumab for neovascular age-related macular degeneration.N Engl J Med. 20063551419–31.
16.
BrownDMMichelsMKaiserPKHeierJSSyJPIanchulevTANCHOR Study Group.Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study.Ophthalmology. 200911657–65.
17.
RegilloCDBrownDMAbrahamPRandomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.Am J Ophthalmol. 2008145239–48.
18.
Schmidt-ErfurthUEldemBGuymerREXCITE Study Group.Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.Ophthalmology. 2011118831–9.
19.
HolzFGAmoakuWDonateJSUSTAIN Study Group.Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.Ophthalmology. 2011118663–71.
20.
IntroiniUTorres GimenoAScottiFSetaccioliMGiatsidisSBandelloFVascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence.Graefes Arch Clin Exp Ophthalmol. 20122501283–92.
21.
AroraSMcKibbinMOne-year outcome after intravitreal ranibizumab for large, serous pigment epithelial detachment secondary to age-related macular degeneration.Eye. 2011251034–8.
22.
ChenEKaiserRSVanderJFIntravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration.Retina. 200727445–50.
23.
LadasIDKotsolisAIPapakostasTDRouvasAAKaragiannisDAVergadosIIntravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.Retina. 200727891–6.
24.
AriasLTreatment of retinal pigment epithelial detachment with antiangiogenic therapy.Clin Ophthalmol. 20104369–74.
25.
ShimaCGomiFSawaMSakaguchiHTsujikawaMTanoYOne-year results of combined photodynamic therapy and intravitreal bevacizumab injection for retinal pigment epithelial detachment secondary to age-related macular degeneration.Graefes Arch Clin Exp Ophthalmol. 2009247899–906.
26.
InoueMArakawaAYamaneSKadonosonoKVariable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy.Retina. 201333990–7.
27.
LommatzschA[Pigment epithelial detachment in exudative macular degeneration: clinical characteristics and therapeutic options.]Ophthalmologe. 20101071115–22.
28.
BolzMMichelsSGeitzenauerWPragerFSchmidt-ErfurthUEffect of systemic bevacizumab therapy on retinal pigment epithelial detachment.Br J Ophthalmol. 200791785–9.
29.
LommatzschAHeimesBGutfleischMSpitalGZeimerMPauleikhoffDSerous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments.Eye. 2009232163–8.
30.
AchTHoehAERuppensteinMKretzFTDithmarSIntravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.Retina. 2010301420–5.
31.
ParodiMBIaconoPPapayannisAIntravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: a prospective 24-month case series.Am J Ophthalmol. 2013155103–8.
32.
BabaTKitahashiMKubota-TaniaiMOshitariTYamamotoSTwo-year course of subfoveal pigment epithelial detachment in eyes with age-related macular degeneration and visual acuity better than 20/40.Ophthalmologica. 2012228102–9.
33.
HoskinABirdACSehmiKTears of detached retinal pigment epithelium.Br J Ophthalmol. 198165417–22.
